Sells complex generic drugs approved by the FDA and repackages pharmaceuticals for the U.S. military and Veterans Affairs.
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 0
- Scale
Sells complex generic drugs approved by the FDA and repackages pharmaceuticals for the U.S. military and Veterans Affairs.
What this company is and how it runs — written from structure, not news.
Amneal Pharmaceuticals earns revenue through two separate gatekeeping mechanisms: FDA approval for complex generics like its biosimilar version of the bone-drug Prolia, and government procurement credentials that let its AvKARE division repackage pharmaceuticals for Veterans Affairs and the Department of Defense. The Prolia biosimilar cannot reach pharmacy shelves until Amneal completes a clinical study proving it works the same way as the original drug, then separately validates the sterile injectable manufacturing lines at each named facility in India and the U.S. — because FDA approval is tied to a specific building, not just a recipe. That sequential requirement means no competitor can shortcut the process by spending more money, but it also means Amneal itself can only advance a handful of complex generics at a time, since each one occupies its own approval track. AvKARE faces a different kind of gatekeeping: VA and DoD procurement systems require vendors to complete a qualification process those agencies control, so competitors cannot enter simply by building a repackaging facility — but if Washington decided to consolidate pharmaceutical purchasing to a smaller list of approved suppliers, the same barrier that keeps rivals out would lock AvKARE out too.
How does this company make money?
The company earns money in three ways. It sells generic pharmaceuticals by the unit to wholesalers and pharmacy chains. Through AvKARE, it sells repackaged drugs to Veterans Affairs and the Department of Defense at government contract prices. It also sells branded drugs — including CREXONT and UNITHROID — through standard pharmaceutical distribution channels.
What makes this company hard to replace?
Veterans Affairs and Department of Defense buyers are locked into multi-year contract and renewal cycles with qualified vendors, so switching to a new supplier is not a quick decision — it means restarting a qualification process the government controls. On the clinical side, getting a denosumab biosimilar onto a hospital's approved drug list requires convincing formulary committees and educating prescribers, which takes time even after the drug is available.
What limits this company?
The FDA approves sterile injectable and ophthalmic manufacturing one product at one facility at a time. So the denosumab biosimilar program and the cyclosporine ophthalmic emulsion program each need their own separate validation process — finishing one does nothing to speed up the other. There is no way to buy or build your way around that queue.
What does this company depend on?
The company cannot run without four things: qualified outside suppliers who provide the active pharmaceutical ingredients used to make the denosumab biosimilar; FDA approval for each Abbreviated New Drug Application across its injectable and ophthalmic product lines; sterile manufacturing facilities in India and Ireland that have passed FDA validation; and the U.S. government contracting credentials that allow AvKARE to repackage and sell pharmaceuticals to federal agencies.
Who depends on this company?
Veterans Affairs medical centers rely on AvKARE's repackaging operations to receive their drug supplies — if those operations stopped, those facilities would face purchasing disruptions. Ophthalmology practices that treat dry eye depend on the company's generic cyclosporine emulsion supply. Oncology and osteoporosis treatment centers count on a steady supply of the denosumab biosimilar as a lower-cost alternative to Prolia and XGEVA.
How does this company scale?
Adding capacity for established products like albuterol inhalers is straightforward — the company can build more production lines or expand a facility. But every new complex generic, like the denosumab biosimilar, requires its own clinical study and its own factory validation process. That regulatory work cannot be sped up by spending more money, so the pipeline of complex generics grows slowly no matter how large the company gets.
What external forces can significantly affect this company?
When the Indian rupee weakens or strengthens against the dollar, the cost of running manufacturing facilities in India shifts in ways the company cannot fully control. The revenue that flows through AvKARE depends on how much the U.S. federal budget allocates to Veterans Affairs and Department of Defense pharmaceutical purchasing each year — a political decision made in Washington. And if the European Medicines Agency changes its rules, those changes could affect what the Irish manufacturing facility is allowed to produce or export.
Where is this company structurally vulnerable?
If Veterans Affairs or the Department of Defense decided to shrink their approved-vendor lists or started buying directly from drug manufacturers instead of repackagers, AvKARE's qualification credentials would stop being valuable. The same government-controlled gate that keeps competitors out would also shut AvKARE out.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Three financing observations align: debt issuance is large relative to operating cash flow, absolute financing cash flow is large relative to operating cash flow, and long-term debt is a large share of total debt. Together they describe heavy financing activity with a long-term-debt-dominant mix.
How does this company use capital?
Net profit margin is positive while depreciation is a meaningful share of operating cash flow. The composition note: a non-trivial part of the earnings-to-cash bridge is depreciation specifically.
Three observations co-occur: free cash flow has been positive each of the last three fiscal years, ADX directional-movement asymmetry is elevated, and the 50-week SMA sits above the 200-week SMA. The set describes past free-cash-flow generation alongside lopsided directional movement and a present-state price/SMA geometry.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph